Potentials for endoscopic and magnetic resonance diagnostic methods in assessing the radicality of chemoradiotherapy in patients with rectal cancer
- Authors: Salimova A.A.1, Makarova M.V.2, Besova N.S.1, Kuvshinov Y.P.1, Karasev I.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Regional Oncology Dispensary
- Issue: Vol 31, No 7 (2024)
- Pages: 82-88
- Section: Original articles
- URL: https://bakhtiniada.ru/2073-4034/article/view/279019
- DOI: https://doi.org/10.18565/pharmateca.2024.7.82-88
- ID: 279019
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background. One of the treatment options for patients with a histologically verified diagnosis of rectal cancer (RC) after chemoradiotherapy (CRT) at the first stage with a complete clinical response is an organ-preserving method consisting in follow-up. Given the possible risks of choosing this observation method, including continued tumor growth, high accuracy in assessing the response to CRT is required. The response of the rectum to CRT is assessed based on the results of a set of physical and instrumental diagnostic methods, including digital rectal examination, rectoscopy, and magnetic resonance imaging (MRI).
Objective. Comparison of the accuracy of the endoscopic examination method, supplemented by mandatory biopsy material collection, and MRI in assessing the complete clinical response after CRT.
Methods. In the period from 2017 to 2023, 117 patients with verified cancer of the middle and lower ampullar parts of the rectum were examined and treated at the N.N. Trapeznikov Research Institute of Cancer Research, N.N. Blokhin National Medical Research Center of Oncology. All patients underwent neoadjuvant CRT at the first stage of complex therapy.
Results. The effectiveness of the therapy was assessed based on the results of a clinical examination, including MRI and colonoscopy with biopsy. The reference standard for assessing the accuracy of the examination results was the conclusion of a histological examination based on the material taken during colonoscopy from the site of a previously localized tumor.
Conclusion. Clinical assessment of the performed CRT using a combination of MRI and endoscopy (+ biopsy) is the most accurate and effective strategy for identifying patients with a residual tumor or patients with a likelihood of continued growth, especially in some cases where it is possible to delay surgical treatment and maintain the patient’s functional status. The addition of MRI (including DWI) to an endoscopic examination improves diagnostic indicators and their combination can be recommended as a diagnostic algorithm after CRT.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Alina A. Salimova
N.N. Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: alina.salimova@gmail.com
ORCID iD: 0000-0002-5614-8405
Postgraduate Student, Endoscopy Department, N.N. Trapeznikov Research Institute of Clinical Oncology
Russian Federation, MoscowM. V. Makarova
Regional Oncology Dispensary
Email: alina.salimova@gmail.com
ORCID iD: 0000-0002-5277-7757
Russian Federation, Saratov
N. S. Besova
N.N. Blokhin National Medical Research Center of Oncology
Email: alina.salimova@gmail.com
ORCID iD: 0000-0002-1693-0523
SPIN-code: 7464-5830
N.N. Trapeznikov Research Institute of Clinical Oncology
Russian Federation, MoscowYu. P. Kuvshinov
N.N. Blokhin National Medical Research Center of Oncology
Email: alina.salimova@gmail.com
ORCID iD: 0009-0002-9802-1119
N.N. Trapeznikov Research Institute of Clinical Oncology
Russian Federation, MoscowI. A. Karasev
N.N. Blokhin National Medical Research Center of Oncology
Email: alina.salimova@gmail.com
ORCID iD: 0000-0002-7025-970X
N.N. Trapeznikov Research Institute of Clinical Oncology
Russian Federation, MoscowReferences
- Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44. doi: 10.1016/S1470-2045(10)70172-8.
- Sanghera P., Wong D.W., McConkey C.C., et al. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol. 2008;20(2):176–83. doi: 10.1016/j.clon.2007.11.013.
- Marijnen C. OC-0429 Neoadjuvant chemoradiotherapy or 5×5 Gy followed by chemotherapy in rectal cancer: the RAPIDO trial. ESTRO 36 abstract book 2017.
- Hospers G., Bahadoer R.R., Dijkstra E.A., et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. ASCO Meeting Library. 2020 May 13, on-line.
- Conroy T., Lamfichekh N., Etienne P.-L., et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. Am Soc Clin Oncol. 2020; 38:4007.
- Conroy T., Bosset J., Etienne P., et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15. doi: 10.1016/S1470-2045(21)00079-6.
- Jin J., Tang Y., Hu C., et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022;40(15):1681–92. doi: 10.1200/JCO.21.01667.
- Basch E., Dueck A.C., Mitchell S.A., et al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023;41(21):3724–34. doi: 10.1200/JCO.23.00903.
- Fernandez-Martos C. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26(8):1722–8. doi: 10.1093/annonc/mdv223.
- Thompson H.M., Omer D.M., Lin S., et al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2350903. doi: 10.1001/jamanetworkopen.2023. 50903.
- Beets-Tan R.G.H., Lambregts D.M.J., Maas M., et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations. From the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28:1465–75. doi: 10.1007/s00330-017-5026-2.
- Patel U.B., Brown G., Rutten H., et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2012;19:2842–52. doi: 10.1245/s10434-012-2309-3.
- Taylor F.G., Swift R.I., Blomqvist L., Brown G. A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. AJR Am J Roentgenol. 2008;191: 1827–35.
- Patel U.B., Blomqvist L.K., Taylor F., et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response the MERCURY experience. AJR Am J Roentgenol. 2012;199:W486–95. doi: 0.2214/AJR.11.8210.
- Stijns R.C.H., Leijtens J., de Graaf E., et al. Endoscopy and MRI for restaging early rectal cancer after neoadjuvant treatment. Colorectal Dis. 2023;25(2):211–21. doi: 10.1111/codi.16341.
Supplementary files
